Aptose Biosciences Inc (APTO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH61222D
- Pages: 59
- November 2018
- Total Views:1285
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company which focuses on diagnostics, therapies and treatment for patients with life-threatening cancers. The company advances in new therapeutics which focuses on cellular targets of cancer research coupled with companion diagnostics to identify patient with cancer. Its small molecule cancer therapeutics pipeline includes products which are designed to provide single agent efficacy and efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The company's product portfolio comprises of CG'806, is a non-covalent small molecule therapeutic agent. Aptose is headquartered in Toronto, Ontario, Canada.
Aptose Biosciences Inc (APTO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aptose Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 11
Private Equity 11
Aptose Biosciences to Raise up to USD20 Million in Financing 11
Partnerships 13
Aptose Biosciences Enters into Agreement with Laxai Avanti Life Sciences 13
Lorus Therapeutics Enters Into Agreement With Brock University To Develop Novel Anticancer Drugs 14
Cancer Research UK Enters Into Co-Development Agreement With Lorus To Develop Cancer Drug 15
Licensing Agreements 17
Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 17
OHM Oncology Enters into Licensing Agreement with Aptose Biosciences 18
Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 19
Equity Offering 20
Aptose Biosciences Files Shelf Prospectus to Raise up to USD100 Million in Public Offering of Shares 20
Aptose Biosciences Raises Funds through Public Offering of Shares 21
Lorus Therapeutics Completes Underwriters Exercise Of Over-Allotment Option Of Public Offering Of Shares For USD 25.3 Million 22
Lorus Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For Public Offering Of Shares For USD 7.7 Million 24
Lorus Therapeutics Completes Private Placement Of Units For USD 0.9 Million 26
Lorus Therapeutics Completes Private Placement Of Units For USD 6.6 Million 27
Aptose Biosciences Inc-Key Competitors 29
Aptose Biosciences Inc-Key Employees 30
Aptose Biosciences Inc-Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Nov 06, 2018: Aptose reports results for the third quarter ended september 30, 2018 32
Aug 07, 2018: Aptose reports results for the second quarter ended june 30, 2018 35
May 10, 2018: Aptose Reports Results for the First Quarter Ended March 31, 2018 37
Mar 27, 2018: Aptose Reports Results for the Fourth Quarter and Year Ended December 31, 2017 39
Nov 14, 2017: Aptose Reports Results for the Third Quarter Ended September 30, 2017 41
Aug 08, 2017: Aptose Reports Results for the Second Quarter Ended June 30, 2017 43
May 11, 2017: Aptose Reports Results for the First Quarter Ended March 31, 2017 45
Mar 28, 2017: Aptose Reports Fourth Quarter and Year End 2016 Results 47
Corporate Communications 51
Aug 15, 2018: Aptose Biosciences appoints Carol Ashe as Board Director 51
Apr 25, 2018: Aptose Names Caroline M. Loewy As Board Director 52
Mar 27, 2017: Aptose Announces Planned Departure of Chief Business Officer 53
Legal and Regulatory 54
Feb 07, 2018: Aptose Biosciences Files New Preliminary Base Shelf Prospectus to Replace Expired Base Prospectus 54
Product Approvals 55
Jun 29, 2018: FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers 55
Clinical Trials 56
Jun 04, 2018: Aptose Announces Two Publications of Preclinical Data Elucidating the Anticancer Mechanism of Action of APTO-253 56
Apr 17, 2018: Aptose Presents Preclinical Data on APTO-253 at 2018 AACR Annual Meeting 57
Mar 15, 2018: Aptose to Present Preclinical Data of APTO-253 at the 2018 AACR Annual Meeting 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59
List Of Figure
List of Figures
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List Of Table
List of Tables
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aptose Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aptose Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aptose Biosciences to Raise up to USD20 Million in Financing 11
Aptose Biosciences Enters into Agreement with Laxai Avanti Life Sciences 13
Lorus Therapeutics Enters Into Agreement With Brock University To Develop Novel Anticancer Drugs 14
Cancer Research UK Enters Into Co-Development Agreement With Lorus To Develop Cancer Drug 15
Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 17
OHM Oncology Enters into Licensing Agreement with Aptose Biosciences 18
Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 19
Aptose Biosciences Files Shelf Prospectus to Raise up to USD100 Million in Public Offering of Shares 20
Aptose Biosciences Raises Funds through Public Offering of Shares 21
Lorus Therapeutics Completes Underwriters Exercise Of Over-Allotment Option Of Public Offering Of Shares For USD 25.3 Million 22
Lorus Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For Public Offering Of Shares For USD 7.7 Million 24
Lorus Therapeutics Completes Private Placement Of Units For USD 0.9 Million 26
Lorus Therapeutics Completes Private Placement Of Units For USD 6.6 Million 27
Aptose Biosciences Inc, Key Competitors 29
Aptose Biosciences Inc, Key Employees 30
Aptose Biosciences Inc, Other Locations 31
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Aptose Biosciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company which focuses on diagnostics, therapies and treatment for patients with life-threatening cancers. The company advances in new therapeutics which focuses on cellular targets of cancer research coupled with companion diagnostics to identify patient with cancer. Its small molecule cancer therapeutics pipeline includes products which are designed to provide single agent efficacy and efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The company's product portfolio comprises of CG'806, is a non-covalent small molecule therapeutic agent. Aptose is headquartered in Toronto, Ontario, Canada.
Aptose Biosciences Inc (APTO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aptose Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 11
Private Equity 11
Aptose Biosciences to Raise up to USD20 Million in Financing 11
Partnerships 13
Aptose Biosciences Enters into Agreement with Laxai Avanti Life Sciences 13
Lorus Therapeutics Enters Into Agreement With Brock University To Develop Novel Anticancer Drugs 14
Cancer Research UK Enters Into Co-Development Agreement With Lorus To Develop Cancer Drug 15
Licensing Agreements 17
Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 17
OHM Oncology Enters into Licensing Agreement with Aptose Biosciences 18
Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 19
Equity Offering 20
Aptose Biosciences Files Shelf Prospectus to Raise up to USD100 Million in Public Offering of Shares 20
Aptose Biosciences Raises Funds through Public Offering of Shares 21
Lorus Therapeutics Completes Underwriters Exercise Of Over-Allotment Option Of Public Offering Of Shares For USD 25.3 Million 22
Lorus Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For Public Offering Of Shares For USD 7.7 Million 24
Lorus Therapeutics Completes Private Placement Of Units For USD 0.9 Million 26
Lorus Therapeutics Completes Private Placement Of Units For USD 6.6 Million 27
Aptose Biosciences Inc-Key Competitors 29
Aptose Biosciences Inc-Key Employees 30
Aptose Biosciences Inc-Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Nov 06, 2018: Aptose reports results for the third quarter ended september 30, 2018 32
Aug 07, 2018: Aptose reports results for the second quarter ended june 30, 2018 35
May 10, 2018: Aptose Reports Results for the First Quarter Ended March 31, 2018 37
Mar 27, 2018: Aptose Reports Results for the Fourth Quarter and Year Ended December 31, 2017 39
Nov 14, 2017: Aptose Reports Results for the Third Quarter Ended September 30, 2017 41
Aug 08, 2017: Aptose Reports Results for the Second Quarter Ended June 30, 2017 43
May 11, 2017: Aptose Reports Results for the First Quarter Ended March 31, 2017 45
Mar 28, 2017: Aptose Reports Fourth Quarter and Year End 2016 Results 47
Corporate Communications 51
Aug 15, 2018: Aptose Biosciences appoints Carol Ashe as Board Director 51
Apr 25, 2018: Aptose Names Caroline M. Loewy As Board Director 52
Mar 27, 2017: Aptose Announces Planned Departure of Chief Business Officer 53
Legal and Regulatory 54
Feb 07, 2018: Aptose Biosciences Files New Preliminary Base Shelf Prospectus to Replace Expired Base Prospectus 54
Product Approvals 55
Jun 29, 2018: FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers 55
Clinical Trials 56
Jun 04, 2018: Aptose Announces Two Publications of Preclinical Data Elucidating the Anticancer Mechanism of Action of APTO-253 56
Apr 17, 2018: Aptose Presents Preclinical Data on APTO-253 at 2018 AACR Annual Meeting 57
Mar 15, 2018: Aptose to Present Preclinical Data of APTO-253 at the 2018 AACR Annual Meeting 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59
List Of Figure
List of Figures
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List Of Table
List of Tables
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aptose Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aptose Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aptose Biosciences to Raise up to USD20 Million in Financing 11
Aptose Biosciences Enters into Agreement with Laxai Avanti Life Sciences 13
Lorus Therapeutics Enters Into Agreement With Brock University To Develop Novel Anticancer Drugs 14
Cancer Research UK Enters Into Co-Development Agreement With Lorus To Develop Cancer Drug 15
Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 17
OHM Oncology Enters into Licensing Agreement with Aptose Biosciences 18
Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 19
Aptose Biosciences Files Shelf Prospectus to Raise up to USD100 Million in Public Offering of Shares 20
Aptose Biosciences Raises Funds through Public Offering of Shares 21
Lorus Therapeutics Completes Underwriters Exercise Of Over-Allotment Option Of Public Offering Of Shares For USD 25.3 Million 22
Lorus Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For Public Offering Of Shares For USD 7.7 Million 24
Lorus Therapeutics Completes Private Placement Of Units For USD 0.9 Million 26
Lorus Therapeutics Completes Private Placement Of Units For USD 6.6 Million 27
Aptose Biosciences Inc, Key Competitors 29
Aptose Biosciences Inc, Key Employees 30
Aptose Biosciences Inc, Other Locations 31
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Aptose Biosciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
: +91 9015378249
Related Reports
Page 69 | 
May 2022
Page 76 | April 2022
Page 68 | March 2022
Page 78 | March 2022
Page 56 | October 2021